GlassScriptPhysician profile
Alan Tenczar
NPI 1689626194
$1,502.61
in general payments reported to CMS, 2019-2025
12 companies · $20.82 in 2025
The $20.82 reported for 2025 was less than what a typical Foot & Ankle Surgery provider received nationally (typical 2025 total: $424).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $83.85 · 2022: $45.27 · 2023: $390 · 2024: $963 · 2025: $20.82.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Long Term Medical Supply Or Device Loan: $765 · Food and Beverage: $608.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Long Term Medical Supply Or Device Loan | $765.33 |
| Food and Beverage | $608.16 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Integra Lifesciences Corporation | $765.33 | 2024 | Acell |
| Stryker Corporation | $288.10 | 2023 | Actishield, Prostep, Augment Injectable |
| Kerecis Limited | $155.09 | 2024 | Kerecis Omega3 Marigen, Kerecis Omega3 Surgiclose, Kerecis Omega3 Graftguide |
| Smith+Nephew, INC. | $88.73 | 2019-2023 | Bone Anchors With Arthroscopic Delivery System |
| Medtronic, INC. | $46.07 | 2022-2023 | Venaseal |
| Treace Medical Concepts, INC. | $45.02 | 2024-2025 | |
| Djo, LLC | $25.16 | 2019 | |
| Sanara Medtech INC. | $22.94 | 2023 | Celleraterx |
| Bioventus LLC | $20.27 | 2022 | |
| Convatec INC. | $18.52 | 2024 | |
| Merck Sharp & Dohme LLC | $15.05 | 2019 | |
| Acell, INC. | $12.33 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Alan Tenczar listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.